MAP2K7 and melanoma: Concerning BRAF-mutant melanomas, two types of new drugs were introduced in therapy in recent years: one represented by drugs directly and specifically targeting either BRAF-mutant molecules or MEK, and the other one represented by immune check inhibitors—drugs targeting molecules that negatively regulate the immune response.